(RXRX) – Company Press Releases
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Publishes Annual Environmental, Social and Governance Report
-
Recursion Announces Plans to Open New Office in London
-
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Recursion to Host Public L(earnings) Call on February 27
-
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
-
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
-
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
-
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
-
Bayer and Recursion focus research collaboration on Oncology
-
Bayer and Recursion Focus Research Collaboration on Oncology
-
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
-
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
-
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
-
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
-
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
-
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
-
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
-
Recursion to Participate in Upcoming Investor Conferences
-
Altitude Lab Relocates to Gateway’s BioHive Hub
-
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
-
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Publishes Second Annual Environmental, Social and Governance Report
-
Recursion Publishes Second Annual Environmental, Social and Governance Report
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
-
Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
-
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
-
Recursion to Participate in Upcoming Investor Conferences
Back to RXRX Stock Lookup
